glp-1 drugs and fatty liver Therapeutic Mechanisms Clinical Effects of Glucagon-like Peptide 1 Receptor Agonists in Nonalcoholic Disease GLP-1 Medications: Everything You Need
Description
doi: 10.3390/ijms21041509 [DOI] [PMC free article] [PubMed] [Google Scholar] 33.Rao Kondapally Seshasai S, Kaptoge S, Thompson A, et al
The researchers compared breast cancer survival for GLP-1 drugs with that of current diabetes therapies
Semaglutide at the 2.4 mg dose (the maximum approved for weight management) produces roughly 15-17% body weight reduction in clinical trials
Behaviour rather than trend The long-term outlook depends partly on how widely these medications spread
GSPT1 degradation has emerged as a promising therapeutic strategy in oncology, but its essential role in normal cellular proliferation creates a narrow therapeutic window
L., Davies, M., et al
